FINHUB Insights

VTRS · Q3 FY25 · Jul 1 – Sep 30, 2025

Viatris Q3 FY25: where the revenue came from and where it went

Viatris Q3 FY25: revenue $3.8B (+0% year over year). Net profit $0B. Largest cohort Brands $2.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 6, 2025 10-Q
Sankey diagram of Viatris's income statement for Q3 FY25: revenue of $3.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.8B +0% year over year
Gross profit$1.4B 36% margin
Operating profit$0.2B 5% margin
Net profit$0B 0% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 3.8 100% +0%
Brands 2.4 63% +3%
Lipitor 0.4 11% +5%
Other 0.2 5%
Epi Pen Auto Injectors 0.2 5% +28%
Lyrica 0.1 3% −3%
Influvac 0.1 3% +3%
Creon 0.1 3% +10%
Celebrex 0.1 3% −1%
Cost of revenue−2.463%
Gross profit1.436% margin−2pp
Research & development−0.37%+1pp
SG&A−0.824%−3pp
Other−0.11%+0pp
Operating profit0.25% margin−1pp
Tax−0.1
Interest & other costs−0.1
Net profit00%+0pp
Filing on EDGAR More quarters of VTRS

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters